Viridian Therapeutics (VRDN) is in focus after the U.S. Food and Drug Administration approved Lumvoa for thyroid eye disease, covering both active and chronic forms. The stock moved 6% higher after hours.

Viridian Therapeutics’ latest FDA approval comes after a mixed stretch for holders, with the share price down 40.11% year to date but a 1 year total shareholder return of 26.99%. This suggests sentiment has shifted recently as new catalysts such as Lumvoa gain attention.

If Lumvoa’s approval has you looking more closely at healthcare and AI, this could be a useful moment to widen your watchlist using our screener of 40 healthcare AI stocks

With Viridian Therapeutics now holding an approved thyroid eye disease treatment and the stock still down sharply year to date, investors face a key question: is this weakness a potential entry point, or has the market already priced in future growth?

Preferred Price-to-Sales of 28.6x: Is It Justified for Viridian Therapeutics?

Viridian Therapeutics is trading at a P/S ratio of 28.6x, which sets a high bar when you line it up against both peers and the wider biotech sector.

The P/S ratio compares the company’s market value to its revenue, so a higher figure usually means investors are paying more for each dollar of current sales. For a company like Viridian Therapeutics, which is still loss making with revenue of $70.918 million and a net loss of $303.267 million, a rich sales multiple often reflects expectations about future growth rather than current profitability.

According to Simply Wall St’s checks, VRDN is considered expensive on this measure. The P/S of 28.6x is well above the US Biotechs industry average of 12.4x and also above a peer group average of 17.9x. A fair P/S ratio estimate of 0x in the SWS model further underlines how far current pricing is from that reference level. This implies a very large premium relative to what the fair ratio suggests the market could move towards if sentiment or growth expectations change.

Result: Price-to-Sales of 28.6x (OVERVALUED)

However, Viridian Therapeutics still carries clear risks, including ongoing net losses of $303.267 million and a market value of about $2.1 billion that rests on early-stage programs.

Another View: SWS DCF Model Points to a Very Different Picture for Viridian Therapeutics

The high 28.6x P/S ratio suggests Viridian Therapeutics is expensive on sales, but the SWS DCF model sends a very different signal, with an estimated fair value of $135.06 versus the current $18.38 share price. That wide gap frames the stock as deeply undervalued using this method. Which signal matters more for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split on Viridian Therapeutics, this is a good time to move quickly, review the full data set, and form your own takeaway using the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond Viridian Therapeutics?

If Viridian Therapeutics has caught your attention, do not stop there. Broaden your opportunity set with a few focused stock idea lists built from the Simply Wall St screener.

• Target dependable income by reviewing companies in the 10 dividend fortresses that combine higher yields with a focus on stability.
• Hunt for potential mispricing by scanning the 44 high quality undervalued stocks where quality and valuation filters work together to surface ideas.
• Prioritize capital preservation by checking out the 74 resilient stocks with low risk scores aimed at businesses with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.